JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • December 7th, 2015 • Laidlaw & Company (Uk) Ltd. • Pharmaceutical preparations
This Agreement (this “Agreement”) is made and entered into as of December 4, 2015, by and among (1) Laidlaw & Company (UK) Ltd., a full-service investment banking and brokerage firm incorporated in England & Wales (“Laidlaw”), Matthew D. Eitner and James P. Ahern (collectively, the “Laidlaw Parties”) and (2) Dr. John H. Leaman, Todd Johnson, Ben Snedeker, David Buchen and Timothy S. Callahan (Messrs. Leaman, Johnson, Snedeker, Buchen and Callahan, collectively the “Nominees” and, such Nominees together with the Laidlaw Parties, the “Parties” or, the “Group” and each, a “Party”).
TERMINATION OF JOINT FILING AND SOLICITATION AGREEMENTTermination of Joint Filing and Solicitation Agreement • June 2nd, 2016 • Laidlaw & Company (Uk) Ltd. • Pharmaceutical preparations
This Agreement (this “Agreement”) is made and entered into as of June 1, 2016, by and among (1) Laidlaw & Company (UK) Ltd., a company organized in England & Wales (“Laidlaw”), Matthew D. Eitner, James P. Ahern, Dr. John H. Leaman, Todd Johnson, Ben Snedeker, David Buchen and Timothy S. Callahan.
LAIDLAW LETTERHEAD]Nomination Agreement • December 7th, 2015 • Laidlaw & Company (Uk) Ltd. • Pharmaceutical preparations
This letter agreement (this “Agreement”) refers to your agreement to be nominated by Laidlaw & Company (UK) Ltd., a private limited company incorporated in England and Wales (“Laidlaw”) for election to, or to fill a vacancy on, the Board of Directors of Relmada Therapeutics, Inc. (the “Board”), a Nevada corporation (the “Company”). Laidlaw currently is considering nominating you and/or certain other persons (each, a “Nominee”), at the annual or a special meeting of the Company’s stockholders, for election to the Board and/or, following a consent solicitation to expand the Board, to fill vacancies on the Board and currently plans to solicit proxies or consents (the “Solicitation”) in furtherance of the same. By executing this Agreement, you agree that, if Laidlaw selects you as a Nominee, you will fully and actively participate in the Solicitation, and you will devote the time and energy reasonably required to conduct an effective campaign for the election of you and the other Nominees
ADVISORY AND CONSULTING AGREEMENTAdvisory and Consulting Agreement • October 22nd, 2015 • Laidlaw & Company (Uk) Ltd. • Pharmaceutical preparations
This Advisory and Consulting Agreement (“Agreement”) dated September 25, 2015 and effective September 25, 2015 (the “Effective Date”) by and between Laidlaw & Co. (UK) Ltd. with a business address at 546 Fifth Avenue, 23rd Floor, New York, NY 10016 (“Company”), and Trevor Lane Advisory LLC (“Consultant”) a Pennsylvania limited liability company.
JOINT FILING AGREEMENTJoint Filing Agreement • October 22nd, 2015 • Laidlaw & Company (Uk) Ltd. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of a statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, $0.001 par value per share, of Relmada Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 21st day of October, 2015.
